N
Overview
Novo Holdings manages the assets and wealth of the Novo Nordisk Foundation and controls major companies such as Novo Nordisk A/S and Novonesis A/S. It runs a diversified investment portfolio across equities, bonds, real estate, infrastructure, and private equity with a long-term return horizon. It also leads life sciences investing through Seeds, Venture, Principal, and Planetary Health Investments to fund companies at all stages of development. Its goal is to grow and safeguard the Foundation’s wealth while advancing life sciences and planetary health through its investments.
Work here?Claim your company
Simplify's take
What believers are saying
- September 10, 2026, ForYou Medical expanded Novo Holdings’ China wound-care manufacturing exposure.
- April 2026 Route 92 financing and September 2026 AnaCardio round show strong private-deal flow.
- July 2026 Myricx Bio agreed to Novartis acquisition, proving portfolio companies can return capital quickly.
What critics are saying
- Elizabeth Warren pressed the FTC on November 6, 2026, targeting Novo Holdings-Catalent antitrust exposure.
- Novo Nordisk’s November 2026 manufacturing and ziltivekimab write-downs weaken the cash engine funding Novo Holdings.
- A broad GLP-1 slowdown would crush exits, hiring, and new deal capacity across the platform.
What makes Novo Holdings unique
- Novo Holdings controls Novo Nordisk and Novonesis, managing DKK 694 billion at year-end 2025.
- Its portfolio spans seed, venture, principal, planetary health, and Asia teams globally.
- On November 6, 2026, it completed Catalent, giving manufacturing-control leverage others lack.
Help us improve and share your feedback! Did you find this helpful?